SULFISOMIDINE

US Previously Marketed

First approved in 1951

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H14N4O2S
Molecular Weight	278.33
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(C)=N1

InChI

InChIKey=YZMCKZRAOLZXAZ-UHFFFAOYSA-N

InChI=1S/C12H14N4O2S/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)

HIDE SMILES / InChI

Description
Sources: http://www.tabletwise.com/medicine/sulphasomidine

Sulfisomidine (INN), also known as sulphasomidine (BAN until 2003), is a sulfonamide antibacterial. It’s used in the treatment, control, prevention, and improvement of the following conditions and symptoms: Lower urinary tract infections; Meningococcal meningitis; Streptococcal pharyngitis; Gum infection; Bacillary dysentery.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
specific fungi 2 Target ID: specific fungi Sources: http://www.tabletwise.com/medicine/sulphasomidine	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Lower urinary tract infections 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7051761	Curative	Approved 8429	Unknown Approved Use Unknown
Meningococcal meningitis 2 Sources: http://www.tabletwise.com/medicine/sulphasomidine	Curative	Approved 8429	Unknown Approved Use Unknown
Streptococcal pharyngitis 4 Sources: http://www.tabletwise.com/medicine/sulphasomidine	Curative	Approved 8429	Unknown Approved Use Unknown
Bacillary dysentery 3 Sources: http://www.tabletwise.com/medicine/sulphasomidine	Curative	Approved 8429	Unknown Approved Use Unknown
Gum infection 2 Sources: http://www.tabletwise.com/medicine/sulphasomidine	Curative	Approved 8429	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1MT0US
BioSynth	J-015595	https://www.biosynth.com/en/products/all-products/products/J-015595.html
LGC Standards	DRE-C17000405	https://www.lgcstandards.com/US/en/p/DRE-C17000405
PubChem	3543157	https://pubchem.ncbi.nlm.nih.gov/compound/3543157

PubMed

Title	Date	PubMed
Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.	1995 Aug	7486915
[Drugs and breastfeeding].	2002 Apr-Jun	12426458
Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry.	2003	12539187
In-vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species.	2007	17287722

Patents

Sample Use Guides

In Vivo Use Guide

2 g twice daily

Route of Administration: Oral

In Vitro Use Guide

The monotherapy of S suis infections with sulfonamides (SULFISOMIDINE was one of them) should not be encouraged because the MIC50 of all sulfonamides investigated was greater than 32 micrograms/ml. The MIC50 of the sulfonamides against B bronchiseptica ranged from 0.5 to 8 micrograms/ml, against P multocida from 2 to 32 micrograms/ml, and against H pleuropneumoniae from 8 to 64 micrograms/ml.

Name

Type

Language

SULFISOMIDINE

Official Name

English

Sulfisomidine [WHO-DD]

Common Name

English

SULFISOMIDINE [MART.]

Common Name

English

sulfisomidine [INN]

Common Name

English

N1-(2,6-DIMETHYL-4-PYRIMIDINYL)SULFANILAMIDE

Systematic Name

English

SULFISOMIDINE [EP IMPURITY]

Common Name

English

N(SUP 1)-(2,6-DIMETHYL-4-PYRIMIDINYL)SULFANILAMIDE

Systematic Name

English

SULPHASOMIDINE

Common Name

English

SULFISOMIDINE [MI]

Common Name

English

SULFISOMIDINE [JAN]

Common Name

English

SULFAISODIMIDINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

J01EB01